Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharvaris NV PHVS

Healthcare Biotechnology
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Recent & Breaking News (NDAQ:PHVS)

Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire September 12, 2022

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.

GlobeNewswire August 22, 2022

Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference

GlobeNewswire July 14, 2022

Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13

GlobeNewswire July 6, 2022

Pharvaris Announces Annual Meeting of Shareholders

GlobeNewswire June 14, 2022

Pharvaris Participates in the Kinin 2022 Conference

GlobeNewswire June 7, 2022

Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)

GlobeNewswire May 16, 2022

Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer

GlobeNewswire May 11, 2022

Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights

GlobeNewswire May 11, 2022

Pharvaris to Participate in BofA Securities 2022 Healthcare Conference

GlobeNewswire May 5, 2022

Pharvaris to Participate in Upcoming April Investor Conferences

GlobeNewswire April 6, 2022

Pharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

GlobeNewswire March 29, 2022

Pharvaris Announces Preclinical Pharmacological Data for Small Molecule PHA121 Published in International Immunopharmacology

GlobeNewswire March 22, 2022

Pharvaris to Participate in Upcoming March Investor Conferences

GlobeNewswire March 3, 2022

Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 9, 2022

Pharvaris Announces Changes to its Board of Directors

GlobeNewswire December 22, 2021

Pharvaris Announces Changes to its Board of Directors

GlobeNewswire December 7, 2021

Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights

GlobeNewswire November 10, 2021

Pharvaris to Participate in Upcoming September Investor Conferences

GlobeNewswire September 3, 2021

Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights

GlobeNewswire July 30, 2021